Physician profile
Will D Miller
NPI 1760883441
$15,904.96
in general payments reported to CMS, 2019-2025
24 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $519 · 2022: $641 · 2023: $1,318 · 2024: $2,150 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,273 · Food and Beverage: $6,102 · Travel and Lodging: $728 · Education: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,273.00 |
| Food and Beverage | $6,101.98 |
| Travel and Lodging | $727.61 |
| Education | $642.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,174.76 | 2021-2025 | |
| Ucb, INC. | $2,103.13 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,908.85 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $943.00 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $884.83 | 2021-2025 | |
| Lilly USA, LLC | $694.38 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $570.10 | 2021-2025 | Ilumya |
| Pfizer INC. | $527.28 | 2021-2025 | |
| Amgen INC. | $478.46 | 2021-2025 | Otezla, Otezla |
| Organogenesis INC. | $381.16 | 2023-2025 | Cygnus Dual, Puraply, Puraply Wound Matrix |
| Dermavant Sciences, INC. | $207.88 | 2023-2024 | Vtama |
| Incyte Corporation | $202.56 | 2022-2025 | Opzelura |
| Organon LLC | $199.93 | 2025 | Vtama |
| Leo Pharma INC. | $181.28 | 2024-2025 | Adbry |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $81.57 | 2022-2025 | |
| Galderma Laboratories, L.P. | $80.20 | 2025 | Nemluvio |
| Biofrontera INC. | $52.42 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Supernus Pharmaceuticals, INC. | $35.48 | 2021 | |
| Genentech USA, INC. | $24.25 | 2023 | Xolair |
| Sanofi Pasteur INC. | $21.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.31 | 2023 | Spevigo |
| Novo Nordisk INC | $18.47 | 2021 | |
| Almirall LLC | $14.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Will Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.